ALLUVI: A DEEP EXPLORATION INTO RETATRUTIDE'S POTENTIAL

Alluvi, previously known as LY3414901, represents a exciting advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist exhibits remarkable efficacy in early medical data, with substantial reduction